New Zealand markets open in 3 hours 3 minutes

Alnylam Pharmaceuticals, Inc. (ALNY)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
176.10+4.74 (+2.77%)
As of 12:57PM EST. Market open.
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2020
31/12/2019
31/12/2018
31/12/2017
Total revenue
749,314
492,853
219,750
74,908
89,912
Cost of revenue
125,504
78,052
25,062
1,802
-
Gross profit
623,810
414,801
194,688
73,106
-
Operating expenses
Research development
731,575
654,819
655,114
505,420
390,635
Selling general and administrative
600,548
588,420
479,005
382,359
199,365
Total operating expenses
1,332,123
1,243,239
1,134,119
887,779
590,000
Operating income or loss
-708,313
-828,438
-939,431
-814,673
-500,088
Interest expense
134,722
84,496
-
-
-
Total other income/expenses net
5,418
45,525
20,730
24,737
-3,022
Income before tax
-835,441
-855,600
-885,253
-760,674
-490,874
Income tax expense
2,463
2,681
863
823
-
Income from continuing operations
-837,904
-858,281
-886,116
-761,497
-490,874
Net income
-837,904
-858,281
-886,116
-761,497
-490,874
Net income available to common shareholders
-837,904
-858,281
-886,116
-761,497
-490,874
Basic EPS
-
-7.46
-8.11
-7.57
-5.42
Diluted EPS
-
-7.46
-8.11
-7.57
-5.42
Basic average shares
-
114,986
109,264
100,590
90,554
Diluted average shares
-
114,986
109,264
100,590
90,554
EBITDA
-
-736,332
-922,256
-808,238
-486,721